Low Covid vaccination coverage: PM Modi to hold review meeting with DMs of over 40 districts

By: |
Updated: October 31, 2021 3:50 PM

The meeting, which will be held via video conferencing, will include districts with less than 50 per cent coverage of the first dose and low coverage of the second dose of the vaccine, it said.

narendra modiModi will be holding the meeting immediately on his return from abroad after attending the G20 and COP26 meetings, the PMO noted. (Photo source: ANI)

Prime Minister Narendra Modi will hold a review meeting on November 3 with district magistrates of over 40 districts having low COVID-19 vaccination coverage, the PMO said on Sunday.

The meeting, which will be held via video conferencing, will include districts with less than 50 per cent coverage of the first dose and low coverage of the second dose of the vaccine, it said.

The 40 districts are spread across Jharkhand, Manipur, Nagaland, Arunachal Pradesh, Maharashtra and Meghalaya among other states, and chief ministers of these states will also attend the meeting.

Modi will be holding the meeting immediately on his return from abroad after attending the G20 and COP26 meetings, the PMO noted. Highlighting the need to accelerate the pace and coverage of vaccination, Union Health Minister Mansukh Mandaviya had recently stated that there are more than 10.34 crore people in the country who have not taken the second dose of the vaccine after the expiry of the prescribed interval.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Serum Institute plans to cut monthly production of Covishield by 50%
2COVID-19: Serum Institute of India may halve Covishield monthly production amid demand slump
3The top myths about Chronic Obstructive Pulmonary Disease